Extracellular Matrix in the Innate Response in Lung Inflammation
肺部炎症先天反应中的细胞外基质
基本信息
- 批准号:8005411
- 负责人:
- 金额:$ 51.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-08-10 至 2015-05-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAdhesionsAgonistAlveolar MacrophagesCoronary heart diseaseDataDiseaseExtracellular MatrixExtracellular SpaceFibroblastsHumanHyaluronanImmune responseImmune systemInfectionInfectious AgentInfiltrationInflammatoryInflammatory ResponseLeukocytesLipopolysaccharidesLungLung InflammationLung diseasesMacromolecular ComplexesMalignant NeoplasmsMediator of activation proteinMusPhasePhenotypePlayProductionProteoglycanPseudomonas aeruginosaPublic HealthPublishingReceptor SignalingRespiratory Syncytial Virus InfectionsRespiratory syncytial virusRoleSeriesSignal PathwayStrokeTLR3 geneTLR4 geneToll-like receptorsViralWorkchemokinecytokineextracellularmacromoleculemacrophagemimeticsmonocyteneutrophilpathogenpreventreceptorresearch studyresponseversican
项目摘要
Lung infecfions place a higher burden on public health than other major diseases such as HIV/AIDS, cancer
coronary heart disease, and strokes (WHO data).^ The innate immune system, which is the body's first line
of defense against lung infecfion, includes pathogen recognition receptors such as Toll-like receptors (TLRs),
producfion of infiammatory mediators such as cytokines and chemokines, and leukocyte recruitment and
acfivafion. There is a paucity of information available with regard to the role of specific extracellular matrix
(ECM) components in the innate immune response. Our preliminary data show that very little versican, an
ECM proteoglycan, is present in healthy lungs but that the TLR4 agonist, lipopolysaccharide (LPS), as well
as Pseudomonas aeruginosa and respiratory syncytial virus (RSV) rapidly increase versican accumulation in
the extracellular space in the lungs of mice. This increase in versican occurs during the eariy phases of lung
inflammation and coincides with leukocyte infiltration. Furthermore, our preliminary experiments show that
human lung fibroblasts treated with the TLR3 agonist and viral mimefic, poly l:C produce a versican-enriched
ECM that forms a macromolecular complex with another extracellular macromolecule, hyaluronan, to
promote monocyte adhesion to the ECM in a versican-dependent manner. Our preliminary results and
published work suggest that versican accumulafion is important in the innate immune response to lung
infection and have led us to formulate our Central Hypothesis, which is that versican plays a key role in the
innate immune response to lung infection by promoting the adhesion, retention, and activation of monocytes,
macrophages and neutrophils. We propose to determine the role of versican in the innate immune response
to lung infection through complefion of the following four Aims: (1) Define the composifion and
compartmentalization of the versican-enriched ECM that accumulates in the lungs of mice exposed to
Pseudomonas aeruginosa and respiratory syncytial virus (RSV) Infecfion and determine its role in leukocyte
adhesion; (2) Determine the TLRs and the TLR signaling pathways responsible for the accumulafion of
versican in the lungs of mice infected with P. aeruginosa and RSV; (3) Define the impact of versican on
macrophage phenotype and function and determine the role of versican produced by pulmonary
macrophages in the innate immune response to lung infecfion; and (4) Determine the requirement for
versican in the innate immune response in the lungs of mice infected with P. aeruginosa and RSV.
与艾滋病毒/艾滋病、癌症等其他主要疾病相比,肺部感染对公共卫生造成的负担更大
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas N Wight其他文献
Fluticasone alone and in combination with salmeterol causes a reduction in the synthesis of proteoglycans by cultured bronchial smooth muscle cells
- DOI:
10.1016/s0091-6749(02)81878-4 - 发表时间:
2002-01-01 - 期刊:
- 影响因子:
- 作者:
Leonard C Altman;Susan Potter-Perigo;Gaylene Altman;Thomas N Wight - 通讯作者:
Thomas N Wight
mooth Muscle Cells of Human Veins Show An Increased Response to Injury at Valve Sites
人体静脉的平滑肌细胞对瓣膜部位损伤的反应增强
- DOI:
- 发表时间:
2017 - 期刊:
- 影响因子:4.3
- 作者:
Shinsuke Kikuchi;Lihua Chen;Kevin Xiong;Yukihiro Saito;Nobuyoshi Azuma;Gale Tang;Michael Sobel;Thomas N Wight;Richard D Kenagy - 通讯作者:
Richard D Kenagy
Thomas N Wight的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas N Wight', 18)}}的其他基金
Targeting the Extracellular Matrix to Inhibit Saphenous Vein Graft (SVG) Failure
靶向细胞外基质抑制隐静脉移植物 (SVG) 失败
- 批准号:
8318591 - 财政年份:2011
- 资助金额:
$ 51.49万 - 项目类别:
Targeting the Extracellular Matrix to Inhibit Saphenous Vein Graft (SVG) Failure
靶向细胞外基质抑制隐静脉移植物 (SVG) 失败
- 批准号:
8200545 - 财政年份:2011
- 资助金额:
$ 51.49万 - 项目类别:
2008 Proteoglycans Gordon Research Conference
2008年蛋白多糖戈登研究会议
- 批准号:
7533667 - 财政年份:2008
- 资助金额:
$ 51.49万 - 项目类别:
Pro-Inflammatory ECM: Key Roles for Hyaluronan and Versican
促炎 ECM:透明质酸和 Versican 的关键作用
- 批准号:
7140040 - 财政年份:2005
- 资助金额:
$ 51.49万 - 项目类别:
Regulation of Cell Function by Matricellular Hevin
基质细胞 Hevin 对细胞功能的调节
- 批准号:
7228904 - 财政年份:2004
- 资助金额:
$ 51.49万 - 项目类别:
Regulation of Cell Function by Matricellular Hevin
基质细胞 Hevin 对细胞功能的调节
- 批准号:
7407527 - 财政年份:2004
- 资助金额:
$ 51.49万 - 项目类别:
Use of Proteoglycan-Genes to Engineer Vascular Tissue
使用蛋白多糖基因改造血管组织
- 批准号:
6661317 - 财政年份:2002
- 资助金额:
$ 51.49万 - 项目类别:
Use of Proteoglycan-Genes to Engineer Vascular Tissue
使用蛋白多糖基因改造血管组织
- 批准号:
6571306 - 财政年份:2002
- 资助金额:
$ 51.49万 - 项目类别:
Use of Proteoglycan-Genes to Engineer Vascular Tissue
使用蛋白多糖基因改造血管组织
- 批准号:
6844178 - 财政年份:2002
- 资助金额:
$ 51.49万 - 项目类别:
Use of Proteoglycan-Genes to Engineer Vascular Tissue
使用蛋白多糖基因改造血管组织
- 批准号:
6787184 - 财政年份:2002
- 资助金额:
$ 51.49万 - 项目类别:
相似海外基金
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y004841/1 - 财政年份:2024
- 资助金额:
$ 51.49万 - 项目类别:
Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
- 批准号:
BB/Y001427/1 - 财政年份:2024
- 资助金额:
$ 51.49万 - 项目类别:
Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y005414/1 - 财政年份:2024
- 资助金额:
$ 51.49万 - 项目类别:
Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
- 批准号:
10669829 - 财政年份:2023
- 资助金额:
$ 51.49万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10587090 - 财政年份:2023
- 资助金额:
$ 51.49万 - 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
- 批准号:
10821599 - 财政年份:2023
- 资助金额:
$ 51.49万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10841832 - 财政年份:2023
- 资助金额:
$ 51.49万 - 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
- 批准号:
10532480 - 财政年份:2022
- 资助金额:
$ 51.49万 - 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
- 批准号:
10741261 - 财政年份:2022
- 资助金额:
$ 51.49万 - 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
- 批准号:
10674894 - 财政年份:2022
- 资助金额:
$ 51.49万 - 项目类别:














{{item.name}}会员




